In vitro and in vivo functional profile characterization of 17‐cyclopropylmethyl‐3,14&bgr;‐dihydroxy‐4,5&agr;‐epoxy‐6&agr;‐(isoquinoline‐3‐carboxamido)morphinan (NAQ) as a low efficacy mu opioid receptor modulator